wtx-330
wtx-330: sourced relationships with 1 company · 2 clinical trials tracked.
wtx-330 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could wtx-330 → HOWL affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Werewolf Therapeutics, Inc. (HOWL) Advanced or Metastatic Solid Tumors | Phase 1/Phase 2 |
Clinical Trial Registry Records (2)
A Phase 1b/2 Multisite Dose- and Regimen-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (NHL)
Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs)
A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients With Advanced or Metastatic Solid Tumors or Lymphoma
Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs)
Frequently asked questions
Which companies have sourced relationships with wtx-330?
wtx-330 has dated SEC/FDA relationship records for Werewolf Therapeutics, Inc..
How many clinical trials involve wtx-330?
BioSniper tracks 2 clinical trials involving wtx-330.